Cara Therapeutics provides pipeline update; KORSUVA Q4 net sales $2.3M, cash $157M

Tvardi Therapeutics, Inc.

KORSUVA injection net sales: $16.8M Q2, $16.2M Q3, $2.3M Q4 2022; profit-share revenue $8.0M/7.4M/1.1M.
Cash $157M, no debt, 54M shares outstanding; runway into at least 1H 2024.
Oral difelikefalin programs: NDD-CKD Phase 3 topline 2H2024; AD Phase 3 topline 1H2025; NP Phase 2/3 internal readout 2H2024.
KORSUVA Japan approval expected 2H2023; Kapruvia EU launched 2H2022 with $72K Q4 royalty.
TDAPA reimbursement at ASP for min 2 years; positive CMS dialogue on post-TDAPA coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.